Blinatumomab Bridging Therapy for BALL

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

October 1, 2022

Study Completion Date

October 1, 2022

Conditions
B-cell Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRelapsed B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Michael Burke

OTHER